Wendy S Lane MD

Endocrinology•Asheville, NC

Diabetes, Lipid Metabolism

Endocrinologist, Mountain Diabetes/Endocrine Center

Join to View Full Profile

141 Asheland AveAsheville, NC 28801
Phone+1 828-258-2404
Fax+1 828-258-0864

Education & Training

Maine Medical CenterFellowship, Endocrinology, Diabetes, and Metabolism, 1992 - 1994
Newton-Wellesley HospitalResidency, Internal Medicine, 1984 - 1987
Geisel School of Medicine at DartmouthClass of 1984

Certifications & Licensure

NH State Medical License 1987 - Present
NC State Medical License 1998 - 2026
SC State Medical License 1995 - 1998
ME State Medical License Active through 1994
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Endocrinology, Diabetes and Metabolism

Clinical Trials

U-500R Insulin In Type 2 Diabetes With Severe Insulin Resistance Via Omnipod Start of enrollment: 2007 Dec 01
Completed
Phase 4
Study of Effectiveness of Liraglutide Added to High Dose Insulin in Type II Diabetics Start of enrollment: 2011 Dec 01
Completed
Phase 4
Open-Label Extension Study to Evaluate Long Term Safety and Treatment Effect of DiaPep277® Start of enrollment: 2013 Oct 01
Terminated
Phase 3
An Administration Method Study of Human Regular U-500 Insulin (LY041001) in Participants With Type 2 Diabetes Mellitus Start of enrollment: 2015 Oct 20
Completed
Phase 3
The Efficacy and Safety of Faster Insulin Aspart (Fiasp®) Compared to Conventional Insulin Aspart (NovoLog®) as Correction Bolus Start of enrollment: 2019 Mar 27
Recruiting
Phase 4
Join now to see all

Publications & Presentations

PubMed

Frequency of hypoglycaemia with basal insulin treatments in adults with type 1 diabetes treated with basal-bolus insulin regimens in treat-to-target trials: A narrativ...
David Russell-Jones, Timothy S Bailey, Wendy Lane, Chantal Mathieu, Ulrik Pedersen-Bjergaard
Diabetic Medicine. 2024-07-01
37 citations
Switching to once-weekly insulin icodec versus once-daily insulin glargine U100 in individuals with basal-bolus insulin-treated type 2 diabetes (ONWARDS 4): a phase 3a...
Chantal Mathieu, Björg Ásbjörnsdóttir, Harpreet S Bajaj, Wendy Lane, Ana Laura S A Matos
Lancet. 2023-06-10
1 citations
Effective Overall Glycaemic Control with Fast-Acting Insulin Aspart Across Patients with Different Baseline Characteristics: A Post Hoc Analysis of the Onset 9 Trial.
Wendy Lane, Elena Favaro, Esteban Jódar, Pranav Kelkar, Alejandra Oviedo
Diabetes Therapy. 2022-04-01

Lectures

Updates in Individualizing Therapy in Type 2 Diabetes: Optimizing Insulin and Non-Insulin Combinations
ENDO 2019 - New Orleans, LA - 3/24/2019
Liraglutide Added to High-Dose Basal/Bolus Insulin in Type 2 Diabetes
Asheville, NC - 6/15/2014

Press Mentions

Paying the Price: Coping with the High Cost of InsulinNovember 26th, 2018